文献速递泌尿生殖与妇科肿瘤放疗

17基因基因组前列腺评分检测对社区癌症中心局限期前列腺癌放疗后生化失败具有预后价值

The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center.
PubMed 文献 · Adv Radiat Oncol · 2023-03-27

本研究回顾性分析2010至2016年在Georgia Urology接受根治性放疗的450例局限期前列腺癌患者,评估Oncotype DX基因组前列腺评分(GPS)与生化失败、远处转移及前列腺癌特异性死亡的关系。结果显示GPS每增加20单位,生化失败风险比为3.08(95%CI 2.11-4.46,P<.001),远处转移风险比为5.19(95%CI 3.06-8.77,P<.001),前列腺癌特异性死亡风险比为13.07(95%CI 4.42-49.39,P<.001),在Black和White患者中均有强预后价值。

要点

  • GPS每增加20单位,生化失败风险比为3.08(95%CI 2.11-4.46,P<.001)。
  • GPS与远处转移(HR 5.19)和前列腺癌特异性死亡(HR 13.07)均强相关。
  • 种族不是生化失败或远处转移的预测因素,GPS在Black和White患者中均有强预后价值。

核心结论

  • 在社区队列中,GPS检测对局限期前列腺癌放疗后的生化失败时间及长期结局具有强预后价值。

研究设计与样本

  • 回顾性研究纳入2010至2016年在Georgia Urology接受根治性放疗的450例局限期前列腺癌患者,中位年龄65岁,35%为Black。
  • 主要目标为评估GPS结果与按Phoenix标准定义的生化失败时间的关联,次要目标为远处转移时间和前列腺癌特异性死亡。
  • 所有分析采用Cox比例风险回归模型,多变量建模的临床病理协变量事先确定。

主要发现

  • GPS结果与生化失败时间存在强单变量关联(每增加20单位的HR=3.08;95%CI 2.11-4.46;P<.001),多变量调整后仍持续存在。
  • GPS与远处转移时间相关(HR=5.19;95%CI 3.06-8.77;P<.001)。
  • GPS与前列腺癌特异性死亡相关(HR=13.07;95%CI 4.42-49.39;P<.001)。
  • 种族不是生化失败时间或远处转移时间的预测因素,GPS在Black和White患者中对所有终点均有强预后价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to assess the association between the Oncotype DX Genomic Prostate Score (GPS) assay and long-term outcomes in men with localized prostate cancer (PCa) after radiation therapy (RT). We hypothesized that the GPS assay is prognostic for biochemical failure (BCF), along with distant metastasis (DM) and PCa-specific mortality in patients with PCa receiving RT. METHODS AND MATERIALS: We retrospectively studied men with localized PCa treated with definitive RT at Georgia Urology from 2010 to 2016. The primary objective was to assess the association between GPS results and time to BCF per the Phoenix criteria; we also assessed time to DM and PCa-specific mortality. We used Cox proportional hazards regression models for all analyses, with clinicopathologic covariates determined a priori for multivariable modeling. RESULTS: A total of 450 patients (median age, 65 years; 35% Black) met eligibility criteria. There was a strong univariable association between GPS result and time to BCF (hazard ratio [HR] per 20-unit increase = 3.08; 95% confidence interval [CI], 2.11-4.46; P < .001), which persisted after adjusting for clinicopathologic characteristics in multivariable analyses. We also observed this association for time to DM (HR = 5.19; 95% CI, 3.06-8.77; P < .001) and PCa-specific mortality (HR = 13.07; 95% CI, 4.42-49.39; P < .001). Race was not a predictor of time to BCF or DM, and the GPS assay was strongly prognostic for all endpoints in Black and White patients. CONCLUSIONS: In a community-based cohort, the GPS assay was strongly prognostic for time to BCF as well as long-term outcomes in men treated with RT for localized PCa.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Canter DJ, Branch C, Shelnutt J, et al. The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center. Adv Radiat Oncol. 2023. PMID: 37152483. doi:10.1016/j.adro.2023.101193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。